Figure 3

HCI fusion protein-induced immune cells lyse tumor cells both in vitro and in vivo. (A) Cytotoxic activity analysis of PBMCs induced by HCI fusion protein. NCI-N87 or SGC7901 cells cocultured with PBMCs at increasing ratios (5:1, 10: 1 and 20:1) in the presence of HCI fusion protein or trastuzumab and CCK-8 assays were used to detect target cell lysates. (B) In vitro cytokine secretion (IL-2, IFN-γ) of PBMCs cells analysis. PBMCs co-cultured with target cells at a 10:1 ratio were treated with HCI fusion protein or trastuzumab for 24 h, and ELISA was used for detection. (C) After the tumor volume of xenograft mice reached approximately 150 mm3, the mice were treated with standard doses once a week, and the volumes of xenograft mouse tumors were recorded for statistical analysis.(*p < 0.05). (D) After the mice were sacrificed, 100 μL of peripheral blood from treated mice was obtained for the in vivo cytokine secretion assay according to the ELISA kit instrument.